Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Uchida, Y.
Right arrow Articles by Murao, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uchida, Y.
Right arrow Articles by Murao, S.

Stroke, Vol 12, 786-792, Copyright © 1981 by American Heart Association


ARTICLES

Role of prostaglandin I2 and thromboxane A2 in recurring reduction of carotid and cerebral blood flow in dogs

Y Uchida and S Murao

The roles of PGI2 and TXA2 in recurring reduction of carotid artery and cerebral blood flow induced by partial constriction of the common carotid artery and cerebral blood flow induced by partial constriction of the common carotid artery were examined in anesthetized dogs. The recurring reduction was eliminated by OKY 046 and 1580 which inhibit TX synthetase, acetylsalicylic acid which inhibits cyclo-oxygenase and lipoxygenase, PGI2 and by papaverine which enhances PGI synthesis. But the recurring reduction was not eliminated by phentolamine. The recurring reduction was induced by epinephrine which activates phospholipase A2 and cyclo-oxygenase and causes platelet aggregation. It was also induced by tranylcypromine which inhibits PGE2 synthetase and, although infrequently, by TXA2. The recurring reduction was also induced by indomethacin that inhibits cyclo-oxygenase. The indomethacin- induced recurring reduction, however, was eliminated not by OKY 046 and 1580 but by PGI2. It is suggested that TXA2 acted as an inducer and PGI2 as an inhibitor in the recurring reduction of carotid artery and cerebral blood flow.